ECM
NPCE icon

ExodusPoint Capital Management’s Neuropace NPCE Stock Holding History

ExodusPoint Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298K Buy
+18,770
New +$302K ﹤0.01% 1357
2026
Q1 		– Sell
-31,803
Closed -$491K – 1924
2025
Q4 		$491K Buy
+31,803
New +$425K ﹤0.01% 1187
2024
Q2 		– Sell
-19,431
Closed -$256K – 1833
2024
Q1 		$256K Sell
19,431
-360
-2% -$5.13K ﹤0.01% 1298
2023
Q4 		$204K Buy
+19,791
New +$158K ﹤0.01% 1273

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

ExodusPoint Capital Management's NPCE Position: Q2 2026 in Review

ExodusPoint Capital Management opened a new position in Neuropace (NPCE) in Q2 2026: 18,770 shares worth $298K. The stake represents ﹤0.01% of the portfolio and ranks #1357 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in NPCE as recently as Q4 2025.

ExodusPoint Capital Management first reported a position in NPCE in Q4 2023 and has held it in 4 quarters since. The position peaked at $491K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • ExodusPoint Capital Management held 18,770 shares of Neuropace worth $298K as of Q2 2026.
  • Neuropace was a new ExodusPoint Capital Management position in Q2 2026.
  • Neuropace made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q2 2026, its #1357 holding.
  • ExodusPoint Capital Management first reported a position in Neuropace in Q4 2023 and has held it in 4 quarters since.
  • ExodusPoint Capital Management's Neuropace position peaked at $491K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.